MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation Phase 2 results presented at 2025 San Antonio Breast Cancer Symposium ...

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the ...

A single microscopic change in our DNA can permanently alter how the brain is built, locking in developmental problems that ...

CAMBRIDGE, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

All the Latest Game Footage and Images from Mutation Phase Mutation Phase is a horror-shooter with a first-person view, which narrates the consequences of experiments with sound waves. You have to ...

The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...

– Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting – – PIK3CA mutations, ...

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive ...